PARP1 and hypoparathyroidism-retardation-dysmorphism syndrome: Therefore, to further explore PARP inhibitors, explore their undiscovered mechanisms, and extend the application of PARP inhibitors to HRD patients will greatly improve the value of PARP inhibitors.